Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2463-2467

  Riedel, David J ^a,c   Weekes, Elizabeth ^b,d   Forrest, Graeme N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; FLUCONAZOLE; GENTAMICIN; METHADONE; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; VANCOMYCIN; VORICONAZOLE; WARFARIN;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; FEMALE; HEART VALVE DISEASES; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 46249111351     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00300-08     Document Type: Article

References (32)

1. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
2. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
3. Cosgrove, S. E., and V. G. Fowler, Jr. 2007. Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia. Semin. Respir. Crit. Care Med. 28:624-631.
4. Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers. 1989. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet ii:1071-1073.
5. Faville, R. J., Jr., D. E. Zaske, E. L. Kaplan, K. Crossley, L. D. Sabath, and P. G. Quie. 1978. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240:1963-1965.
6. Finch, C. K., C. R. Chrisman, A. M. Baciewicz, and T. H. Self. 2002. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162: 985-992.
7. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
8. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. van der Meer, T. S. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
9. Grosset, J., and S. Leventis. 1983. Adverse effects of rifampin. Rev. Infect. Dis. 5(Suppl. 3):S440-S450.
10. Hackbarth, C. J., H. F. Chambers, and M. A. Sande. 1986. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 29:611-613.
11. Hageman, J. C., L. A. Liedtke, R. H. Sunenshine, L. J. Strausbaugh, L. C. McDonald, and F. C. Tenover. 2006. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin. Infect. Dis. 43:e42-e45.
12. Hawkins, C., J. Huang, N. Jin, G. A. Nos kin, T. R. Zembower, and M. Bolon. 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch. Intern. Med. 167:1861-1867.
13. Heldman, A. W., T. V. Hartert, S. C. Ray, E. G. Daoud, T. E. Kowalski, V. J. Pompili, S. D. Sisson, W. C. Tidmore, K. A. vom Eigen, S. N. Goodman, P. S. Lietman, B. G. Petty, and C. Flexner. 1996. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. 101:68-76.
14. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
15. Kaye, K. S., J. J. Engemann, H. S. Fraimow, and E. Abrutyn. 2004. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect. Dis. Clin. N. Am. 18:467-511, viii.
16. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
17. Kollef, M. H. 2007. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45(Suppl. 3):S191-S195.
18. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
19. Li, J. S., D. J. Sexton, N. Mick, R. Nettles, V. G. Fowler, Jr., T. Ryan, T. Bashore, and G. R. Corey. 2000. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin. Infect. Dis. 30:633-638.
20. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
21. Massanari, R. M., and S. T. Donta. 1978. The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest 73:371-375.
22. Micek, S. T. 2007. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3):S184-S190.
23. Miro, J. M., I. Anguera, C. H. Cabell, A. Y. Chen, J. A. Stafford, G. R. Corey, L. Olaison, S. Eykyn, B. Hoen, E. Abrutyn, D. Raoult, A. Bayer, and V. G. Fowler, Jr. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514.
24. Mwangi, M. M., S. W. Wu, Y. Zhou, K. Sieradzki, L. H. de, P. Richardson, D. Bruce, E. Rubin, E. Myers, E. D. Siggia, and A. Tomasz. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 104:9451-9456.
25. Nadji, G., J. P. Remadi, F. Coviaux, A. A. Mirode, A. Brahim, M. Enriquez-Sarano, and C. Tribouilloy. 2005. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart 91:932-937.
26. Schrenzel, J., S. Harbarth, G. Schockmel, D. Genne, T. Bregenzer, U. Flueckiger, C. Petignat, F. Jacobs, P. Francioli, W. Zimmerli, and D. P. Lew. 2004. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin. Infect. Dis. 39:1285-1292.
27. Shelburne, S. A., D. M. Musher, K. Hulten, H. Ceasar, M. Y. Lu, I. Bhaila, and R. J. Hamill. 2004. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob. Agents Chemother. 48:4016-4019.
28. Spratt, B. G. 1994. Resistance to antibiotics mediated by target alterations. Science 264:388-393.
29. Van der Auwera, P., and J. Klastersky. 1983. In vitro study of the combination of rifampin with oxacillin against Staphylococci aureus. Rev. Infect. Dis. 5(Suppl. 3):S509-S514.
30. Vesely, J. J., F. D. Pien, and B. C. Pien. 1998. Rifampin, a useful drug for nonmycobactcrial infections. Pharmacotherapy 18:345-357.
31. Yzerman, E. P., H. A. Boelens, M. Vogel, and H. A. Verbrugh. 1998. Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. J. Antimicrob. Chemother. 42:233-239.
32. Zinner, S. H., H. Lagast, and J. Klastersky. 1981. Antistaphylococcal activity of rifampin with other antibiotics. J. Infect. Dis. 144:365-371.